+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Breast Cancer Screening Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Breast Cancer Screening Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Sale

Breast Cancer Screening Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011427
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Breast Cancer Screening Market grew from USD 5.31 billion in 2024 to USD 5.69 billion in 2025. It is expected to continue growing at a CAGR of 6.86%, reaching USD 7.91 billion by 2030.

Breast cancer screening stands at the forefront of preventive healthcare, offering the critical advantage of early detection and timely intervention. As diagnostic capabilities evolve, the emphasis has shifted from one-size-fits-all approaches to personalized strategies that address individual risk profiles and technological accessibility. Around the globe, stakeholders-from clinicians to policymakers-recognize the imperative to refine screening pathways, improve patient adherence, and leverage cutting-edge modalities. In this dynamic environment, innovations in imaging, data analytics, and patient engagement converge to reshape how screening programs are designed and implemented. This introduction frames the current landscape, highlights prevailing challenges, and previews the transformative shifts that demand strategic action from industry leaders and healthcare decision-makers.

Emerging Transformations Reshaping Screening Practices

In recent years, breast cancer screening has undergone a remarkable metamorphosis, driven by technological breakthroughs, patient-centric care models, and regulatory incentives. Artificial intelligence integration into imaging platforms now enhances lesion detection sensitivity, while augmented reality overlays guide minimally invasive procedures with greater precision. Digital imaging solutions have transitioned from analog film to high-resolution, cloud-connected systems, accelerating diagnostic workflows and enabling remote consultations. Simultaneously, risk-based stratification tools empower clinicians to tailor screening intervals and modalities according to genetic mutations, family history, and breast density. Telehealth platforms facilitate earlier triage and follow-up, fostering continuous engagement with high-risk populations. Collectively, these shifts underscore a move toward more accurate, efficient, and personalized screening pathways that promise tangible improvements in patient outcomes and operational scalability.

Analyzing the 2025 US Tariffs Impact on Breast Cancer Screening

The implementation of new US tariffs in 2025 on medical device components has introduced fresh considerations for equipment manufacturers and healthcare providers. Import duties on high-precision imaging parts affect the cost base for MRI machines, ultrasound transducers, and biopsy instruments, prompting suppliers to reassess supply chains. Providers may experience pressure to absorb incremental costs or pass them through to patients, potentially impacting screening adherence among underinsured populations. In response, several device makers are exploring localized manufacturing partnerships and sourcing alternative components to mitigate margin erosion. At the same time, advocacy groups are engaging policymakers to clarify tariff classifications for critical diagnostic equipment, seeking exemptions that safeguard access to life-saving technologies. As the landscape adapts, collaboration between regulators, manufacturers, and payers will be essential to preserving both affordability and innovation in breast cancer screening.

Deep Dive into Breast Cancer Screening Segment Dynamics

Segment dynamics reveal how diverse patient cohorts, risk profiles, and technological preferences shape overall demand. Based on Screening Methods, practitioners weigh the precision of core needle, fine needle aspiration, and stereotactic biopsies against non-invasive modalities such as breast and functional MRI, 3D, digital and film mammography, infrared and liquid crystal thermography, or automated breast and conventional ultrasound. Age Group segmentation indicates that women under 40 often rely on ultrasound or MRI to overcome dense breast tissue limitations, whereas those in their forties and fifties increasingly adopt digital mammography enhanced by artificial intelligence. Patients aged 60 and above demonstrate higher uptake of functional imaging and advanced biopsy techniques to confirm lesion characterization. Risk Factors further refine strategies, with family history driving earlier baseline screening, BRCA1 and BRCA2 mutation carriers prioritized for annual MRI, and previous radiation exposure warranting combined modality approaches. Cancer Type considerations-ductal carcinoma, lobular carcinoma, or mixed forms-inform both device selection and assay development. End Users span breast clinics and diagnostic centers to private and public hospitals as well as oncology centers, each requiring tailored workflows and service models. Technological Advancements such as AI-driven analytics, augmented reality diagnostic tools, and high-definition digital imaging continue to influence product road maps. Product segmentation differentiates between breast biopsy devices, imaging systems like mammography equipment, MRI machines, ultrasound devices, and a growing suite of molecular and immuno-screening assays. Payment Models range from insurance coverage that supports routine screenings to out-of-pocket payment trends and public healthcare initiatives aimed at underserved populations. Breast Density categories of dense versus non-dense tissue shape modality choice, while Screening Intervals-annual compared to biennial approaches-reflect trade-offs between early detection benefits and resource allocation. Together, these segments provide a comprehensive framework for customizing screening solutions and optimizing resource deployment.

Regional Nuances Driving Screening Adoption

Regional nuances profoundly influence screening adoption and program efficacy. In the Americas, supportive reimbursement policies and established clinical guidelines drive widespread access to advanced imaging modalities, coupled with multi-stakeholder initiatives that target high-risk communities. Europe, the Middle East & Africa present a mosaic of regulatory environments where cost-containment imperatives coexist with pockets of innovation; strategic collaborations and public-private partnerships are crucial for extending screening coverage beyond urban centers. Across the Asia-Pacific region, rising healthcare expenditure, expanding diagnostic infrastructure, and growing patient awareness create fertile ground for deploying both traditional and emerging screening technologies. In each region, aligning product portfolios with local reimbursement frameworks, regulatory requirements, and cultural preferences remains key to unlocking market potential and advancing early detection goals.

Competitive Landscape and Key Player Strategies

Leading companies are steering the industry forward through strategic investments, partnerships, and continuous innovation. Global pharma and life sciences giants such as AstraZeneca plc, Bayer AG, and F. Hoffmann-La Roche Ltd are leveraging their R&D capabilities to co-develop companion diagnostics. Medical device stalwarts including Becton, Dickinson and Company, Carestream Health, Inc., Danaher Corporation, GE HealthCare Technologies Inc., Hologic, Inc., Koninklijke Philips N.V., Siemens Healthineers AG, and Fujifilm Holdings Corporation are enhancing imaging platforms with AI-powered analytics and streamlined user interfaces. Specialty diagnostics firms like Exact Sciences Corporation, Myriad Genetics, Inc., NanoString Technologies, Inc., Oncocyte Corporation, Prelude Corporation, Quest Diagnostics Incorporated, and Vayyar Imaging, Ltd. are pioneering molecular assays and non-invasive screening tools. Emerging innovators such as NIRAMAI Health Analytix Private Limited, OncoStem Diagnostics Pvt. Ltd, and Syantra Inc. focus on region-specific solutions, integrating digital imaging with telehealth services for resource-constrained markets. By forging cross-sector alliances, optimizing regulatory pathways, and scaling manufacturing networks, these players are collectively advancing the precision and accessibility of breast cancer screening.

Strategic Recommendations for Industry Stakeholders

To remain at the vanguard, industry leaders should adopt several strategic imperatives: 1. Integrate artificial intelligence and machine learning across platforms to enhance diagnostic accuracy and reduce false positives, ensuring seamless interoperability with existing clinical systems. 2. Diversify product portfolios by combining imaging devices, biopsy tools, and molecular assays into cohesive screening solutions that address full patient pathways from detection to diagnosis. 3. Form strategic alliances with localized manufacturing partners and academic centers to mitigate tariff impacts, optimize supply chains, and accelerate regulatory approvals. 4. Invest in patient engagement platforms-mobile apps, telehealth interfaces, and personalized risk dashboards-to boost screening adherence and foster data-driven follow-up programs. 5. Tailor market access strategies to regional reimbursement frameworks, aligning pricing models with insurance coverage policies and public healthcare initiatives to expand reach among underinsured populations. 6. Enhance training and education initiatives for radiologists and technicians, leveraging augmented reality and simulation tools to maintain high procedural standards and reduce learning curves. 7. Establish robust data governance and privacy protocols to uphold patient trust while enabling large-scale analytics and real-world evidence generation.

Conclusion: Steering Towards Enhanced Screening Outcomes

Breast cancer screening is poised at a critical inflection point where technology, policy, and patient expectations converge. The integration of AI, digital imaging, and risk-adaptive protocols is redefining what constitutes best practice, while global tariff shifts and regional disparities underscore the importance of supply-chain resilience and market-specific strategies. By harnessing cross-disciplinary partnerships and prioritizing patient engagement, stakeholders can unlock new avenues for early detection and improved outcomes. As the landscape continues to evolve, maintaining agility and fostering collaboration will be essential to deliver on the promise of equitable, high-accuracy screening for all populations.

Market Segmentation & Coverage

This research report categorizes the Breast Cancer Screening Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Biopsy
    • Core Needle Biopsy
    • Fine Needle Aspiration Biopsy
    • Stereotactic Biopsy
  • Magnetic Resonance Imaging (MRI)
    • Breast MRI
    • Functional MRI
  • Mammography
    • 3D Mammography
    • Digital Mammography
    • Film Mammography
  • Thermography
    • Infrared Thermography
    • Liquid Crystal Thermography
  • Ultrasound
    • Automated Breast Ultrasound
    • Breast Ultrasound
  • 40-49 Years
  • 50-59 Years
  • 60 Years and Above
  • Less Than 40 Years
  • Family History of Breast Cancer
  • Genetic Mutations
    • BRCA1 Mutations
    • BRCA2 Mutations
  • Previous Radiation Exposure
  • Ductal Carcinoma
  • Lobular Carcinoma
  • Mixed Ductal/Lobular Carcinoma
  • Breast Clinics
  • Diagnostic Centers
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Oncology Centers
  • Artificial Intelligence Integration
  • Augmented Reality in Diagnostic Tools
  • Digital Imaging
  • Breast Biopsy Devices
  • Imaging Devices
    • Mammography Equipment
    • MRI Machines
    • Ultrasound Devices
  • Screening Assays
  • Insurance Coverage
  • Out-of-Pocket Payment
  • Public Healthcare Initiatives
  • Dense Breasts
  • Non-dense Breasts
  • Annual Screening
  • Biennial Screening

This research report categorizes the Breast Cancer Screening Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Breast Cancer Screening Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AstraZeneca plc
  • Bayer AG
  • Becton, Dickinson and Company
  • Carestream Health, Inc.
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Fujifilm Holdings Corporation
  • GE HealthCare Technologies Inc.
  • GlaxoSmithKline plc
  • Hologic, Inc.
  • Koning Health
  • Koninklijke Philips N.V.
  • Myriad Genetics, Inc.
  • NanoString Technologies, Inc.
  • NIRAMAI Health Analytix Private Limited
  • Novartis AG
  • Oncocyte Corporation
  • OncoStem Diagnostics Pvt. Ltd
  • Pfizer Inc.
  • Prelude Corporation
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Syantra Inc.
  • Vayyar Imaging, Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Breast Cancer Screening Market, by Screening Methods
8.1. Introduction
8.2. Biopsy
8.2.1. Core Needle Biopsy
8.2.2. Fine Needle Aspiration Biopsy
8.2.3. Stereotactic Biopsy
8.3. Magnetic Resonance Imaging (MRI)
8.3.1. Breast MRI
8.3.2. Functional MRI
8.4. Mammography
8.4.1. 3D Mammography
8.4.2. Digital Mammography
8.4.3. Film Mammography
8.5. Thermography
8.5.1. Infrared Thermography
8.5.2. Liquid Crystal Thermography
8.6. Ultrasound
8.6.1. Automated Breast Ultrasound
8.6.2. Breast Ultrasound
9. Breast Cancer Screening Market, by Age Group
9.1. Introduction
9.2. 40-49 Years
9.3. 50-59 Years
9.4. 60 Years and Above
9.5. Less Than 40 Years
10. Breast Cancer Screening Market, by Risk Factors
10.1. Introduction
10.2. Family History of Breast Cancer
10.3. Genetic Mutations
10.3.1. BRCA1 Mutations
10.3.2. BRCA2 Mutations
10.4. Previous Radiation Exposure
11. Breast Cancer Screening Market, by Cancer Type
11.1. Introduction
11.2. Ductal Carcinoma
11.3. Lobular Carcinoma
11.4. Mixed Ductal/Lobular Carcinoma
12. Breast Cancer Screening Market, by End Users
12.1. Introduction
12.2. Breast Clinics
12.3. Diagnostic Centers
12.4. Hospitals
12.4.1. Private Hospitals
12.4.2. Public Hospitals
12.5. Oncology Centers
13. Breast Cancer Screening Market, by Technological Advancements
13.1. Introduction
13.2. Artificial Intelligence Integration
13.3. Augmented Reality in Diagnostic Tools
13.4. Digital Imaging
14. Breast Cancer Screening Market, by Products
14.1. Introduction
14.2. Breast Biopsy Devices
14.3. Imaging Devices
14.3.1. Mammography Equipment
14.3.2. MRI Machines
14.3.3. Ultrasound Devices
14.4. Screening Assays
15. Breast Cancer Screening Market, by Payment Models
15.1. Introduction
15.2. Insurance Coverage
15.3. Out-of-Pocket Payment
15.4. Public Healthcare Initiatives
16. Breast Cancer Screening Market, by Breast Density
16.1. Introduction
16.2. Dense Breasts
16.3. Non-dense Breasts
17. Breast Cancer Screening Market, by Screening Intervals
17.1. Introduction
17.2. Annual Screening
17.3. Biennial Screening
18. Americas Breast Cancer Screening Market
18.1. Introduction
18.2. Argentina
18.3. Brazil
18.4. Canada
18.5. Mexico
18.6. United States
19. Asia-Pacific Breast Cancer Screening Market
19.1. Introduction
19.2. Australia
19.3. China
19.4. India
19.5. Indonesia
19.6. Japan
19.7. Malaysia
19.8. Philippines
19.9. Singapore
19.10. South Korea
19.11. Taiwan
19.12. Thailand
19.13. Vietnam
20. Europe, Middle East & Africa Breast Cancer Screening Market
20.1. Introduction
20.2. Denmark
20.3. Egypt
20.4. Finland
20.5. France
20.6. Germany
20.7. Israel
20.8. Italy
20.9. Netherlands
20.10. Nigeria
20.11. Norway
20.12. Poland
20.13. Qatar
20.14. Russia
20.15. Saudi Arabia
20.16. South Africa
20.17. Spain
20.18. Sweden
20.19. Switzerland
20.20. Turkey
20.21. United Arab Emirates
20.22. United Kingdom
21. Competitive Landscape
21.1. Market Share Analysis, 2024
21.2. FPNV Positioning Matrix, 2024
21.3. Competitive Analysis
21.3.1. AstraZeneca plc
21.3.2. Bayer AG
21.3.3. Becton, Dickinson and Company
21.3.4. Carestream Health, Inc.
21.3.5. Danaher Corporation
21.3.6. Exact Sciences Corporation
21.3.7. F. Hoffmann-La Roche Ltd
21.3.8. Fujifilm Holdings Corporation
21.3.9. GE HealthCare Technologies Inc.
21.3.10. GlaxoSmithKline plc
21.3.11. Hologic, Inc.
21.3.12. Koning Health
21.3.13. Koninklijke Philips N.V.
21.3.14. Myriad Genetics, Inc.
21.3.15. NanoString Technologies, Inc.
21.3.16. NIRAMAI Health Analytix Private Limited
21.3.17. Novartis AG
21.3.18. Oncocyte Corporation
21.3.19. OncoStem Diagnostics Pvt. Ltd
21.3.20. Pfizer Inc.
21.3.21. Prelude Corporation
21.3.22. Quest Diagnostics Incorporated
21.3.23. Siemens Healthineers AG
21.3.24. Syantra Inc.
21.3.25. Vayyar Imaging, Ltd.
22. ResearchAI
23. ResearchStatistics
24. ResearchContacts
25. ResearchArticles
26. Appendix
List of Figures
FIGURE 1. BREAST CANCER SCREENING MARKET MULTI-CURRENCY
FIGURE 2. BREAST CANCER SCREENING MARKET MULTI-LANGUAGE
FIGURE 3. BREAST CANCER SCREENING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BREAST CANCER SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SCREENING METHODS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SCREENING METHODS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY RISK FACTORS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY RISK FACTORS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRODUCTS, 2024 VS 2030 (%)
FIGURE 20. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRODUCTS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PAYMENT MODELS, 2024 VS 2030 (%)
FIGURE 22. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PAYMENT MODELS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BREAST DENSITY, 2024 VS 2030 (%)
FIGURE 24. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BREAST DENSITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SCREENING INTERVALS, 2024 VS 2030 (%)
FIGURE 26. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SCREENING INTERVALS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 30. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 34. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 35. BREAST CANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 36. BREAST CANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BREAST CANCER SCREENING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BREAST CANCER SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SCREENING METHODS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CORE NEEDLE BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY FINE NEEDLE ASPIRATION BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY STEREOTACTIC BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BREAST MRI, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY FUNCTIONAL MRI, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAMMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 3D MAMMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIGITAL MAMMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY FILM MAMMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAMMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY INFRARED THERMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY LIQUID CRYSTAL THERMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AUTOMATED BREAST ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BREAST ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 40-49 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 50-59 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 60 YEARS AND ABOVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY LESS THAN 40 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY RISK FACTORS, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY FAMILY HISTORY OF BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY GENETIC MUTATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BRCA1 MUTATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BRCA2 MUTATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY GENETIC MUTATIONS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PREVIOUS RADIATION EXPOSURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DUCTAL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY LOBULAR CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MIXED DUCTAL/LOBULAR CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BREAST CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ARTIFICIAL INTELLIGENCE INTEGRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AUGMENTED REALITY IN DIAGNOSTIC TOOLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIGITAL IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BREAST BIOPSY DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY IMAGING DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAMMOGRAPHY EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MRI MACHINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY IMAGING DEVICES, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SCREENING ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PAYMENT MODELS, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY INSURANCE COVERAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PUBLIC HEALTHCARE INITIATIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BREAST DENSITY, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DENSE BREASTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY NON-DENSE BREASTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SCREENING INTERVALS, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ANNUAL SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BIENNIAL SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY SCREENING METHODS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY MAMMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY RISK FACTORS, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY GENETIC MUTATIONS, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY IMAGING DEVICES, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY PAYMENT MODELS, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY BREAST DENSITY, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY SCREENING INTERVALS, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA BREAST CANCER SCREENING MARKET SIZE, BY SCREENING METHODS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA BREAST CANCER SCREENING MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA BREAST CANCER SCREENING MARKET SIZE, BY MAMMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA BREAST CANCER SCREENING MARKET SIZE, BY RISK FACTORS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA BREAST CANCER SCREENING MARKET SIZE, BY GENETIC MUTATIONS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA BREAST CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA BREAST CANCER SCREENING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA BREAST CANCER SCREENING MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA BREAST CANCER SCREENING MARKET SIZE, BY IMAGING DEVICES, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA BREAST CANCER SCREENING MARKET SIZE, BY PAYMENT MODELS, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA BREAST CANCER SCREENING MARKET SIZE, BY BREAST DENSITY, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA BREAST CANCER SCREENING MARKET SIZE, BY SCREENING INTERVALS, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL BREAST CANCER SCREENING MARKET SIZE, BY SCREENING METHODS, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL BREAST CANCER SCREENING MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2030 (USD MILLION)
TABLE 115. BRAZIL BREAST CANCER SCREENING MARKET SIZE, BY MAMMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL BREAST CANCER SCREENING MARKET SIZE, BY RISK FACTORS, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL BREAST CANCER SCREENING MARKET SIZE, BY GENETIC MUTATIONS, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL BREAST CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL BREAST CANCER SCREENING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL BREAST CANCER SCREENING MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL BREAST CANCER SCREENING MARKET SIZE, BY IMAGING DEVICES, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL BREAST CANCER SCREENING MARKET SIZE, BY PAYMENT MODELS, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL BREAST CANCER SCREENING MARKET SIZE, BY BREAST DENSITY, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL BREAST CANCER SCREENING MARKET SIZE, BY SCREENING INTERVALS, 2018-2030 (USD MILLION)
TABLE 130. CANADA BREAST CANCER SCREENING MARKET SIZE, BY SCREENING METHODS, 2018-2030 (USD MILLION)
TABLE 131. CANADA BREAST CANCER SCREENING MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 132. CANADA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2030 (USD MILLION)
TABLE 133. CANADA BREAST CANCER SCREENING MARKET SIZE, BY MAMMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 134. CANADA BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 135. CANADA BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 136. CANADA BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 137. CANADA BREAST CANCER SCREENING MARKET SIZE, BY RISK FACTORS, 2018-2030 (USD MILLION)
TABLE 138. CANADA BREAST CANCER SCREENING MARKET SIZE, BY GENETIC MUTATIONS, 2018-2030 (USD MILLION)
TABLE 139. CANADA BREAST CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 140. CANADA BREAST CANCER SCREENING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 141. CANADA BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 142. CANADA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 143. CANADA BREAST CANCER SCREENING MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 144. CANADA BREAST CANCER SCREENING MARKET SIZE, BY IMAGING DEVICES, 2018-2030 (USD MILLION)
TABLE 145. CANADA BREAST CANCER SCREENING MARKET SIZE, BY PAYMENT MODELS, 2018-2030 (USD MILLION)
TABLE 146. CANADA BREAST CANCER SCREENING MARKET SIZE, BY BREAST DENSITY, 2018-2030 (USD MILLION)
TABLE 147. CANADA BREAST CANCER SCREENING MARKET SIZE, BY SCREENING INTERVALS, 2018-2030 (USD MILLION)
TABLE 148. MEXICO BREAST CANCER SCREENING MARKET SIZE, BY SCREENING METHODS, 2018-2030 (USD MILLION)
TABLE 149. MEXICO BREAST CANCER SCREENING MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 150. MEXICO BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2030 (USD MILLION)
TABLE 151. MEXICO BREAST CANCER SCREENING MARKET SIZE, BY MAMMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 152. MEXICO BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 153. MEXICO BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 154. MEXICO BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 155. MEXICO BREAST CANCER SCREENING MARKET SIZE, BY RISK FACTORS, 2018-2030 (USD MILLION)
TABLE 156. MEXICO BREAST CANCER SCREENING MARKET SIZE, BY GENETIC MUTATIONS, 2018-2030 (USD MILLION)
TABLE 157. MEXICO BREAST CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 158. MEXICO BREAST CANCER SCREENING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 159. MEXICO BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 160. MEXICO BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 161. MEXICO BREAST CANCER SCREENING MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 162. MEXICO BREAST CANCER SCREENING MARKET SIZE, BY IMAGING DEVICES, 2018-2030 (USD MILLION)
TABLE 163. MEXICO BREAST CANCER SCREENING MARKET SIZE, BY PAYMENT MODELS, 2018-2030 (USD MILLION)
TABLE 164. MEXICO BREAST CANCER SCREENING MARKET SIZE, BY BREAST DENSITY, 2018-2030 (USD MILLION)
TABLE 165. MEXICO BREAST CANCER SCREENING MARKET SIZE, BY SCREENING INTERVALS, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY SCREENING METHODS, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY MAMMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 172. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 173. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY RISK FACTORS, 2018-2030 (USD MILLION)
TABLE 174. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY GENETIC MUTATIONS, 2018-2030 (USD MILLION)
TABLE 175. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 176. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 177. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 178. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 179. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 180. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY IMAGING DEVICES, 2018-2030 (USD MILLION)
TABLE 181. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY PAYMENT MODELS, 2018-2030 (USD MILLION)
TABLE 182. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY BREAST DENSITY, 2018-2030 (USD MILLION)
TABLE 183. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY SCREENING INTERVALS, 2018-2030 (USD MILLION)
TABLE 184. UNITED STATES BREAST CANCER SCREENING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY SCREENING METHODS, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY MAMMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 191. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 192. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY RISK FACTORS, 2018-2030 (USD MILLION)
TABLE 193. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY GENETIC MUTATIONS, 2018-2030 (USD MILLION)
TABLE 194. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 195. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 196. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 197. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 198. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 199. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY IMAGING DEVICES, 2018-2030 (USD MILLION)
TABLE 200. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY PAYMENT MODELS, 2018-2030 (USD MILLION)
TABLE 201. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY BREAST DENSITY, 2018-2030 (USD MILLION)
TABLE 202. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY SCREENING INTERVALS, 2018-2030 (USD MILLION)
TABLE 203. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 204. AUSTRALIA BREAST CANCER SCREENING MARKET SIZE, BY SCREENING METHODS, 2018-2030 (USD MILLION)
TABLE 205. AUSTRALIA BREAST CANCER SCREENING MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 206. AUSTRALIA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2030 (USD MILLION)
TABLE 207. AUSTRALIA BREAST CANCER SCREENING MARKET SIZE, BY MAMMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 208. AUSTRALIA BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 209. AUSTRALIA BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 210. AUSTRALIA BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 211. AUSTRALIA BREAST CANCER SCREENING MARKET SIZE, BY RISK FACTORS, 2018-2030 (USD MILLION)
TABLE 212. AUSTRALIA BREAST CANCER SCREENING MARKET SIZE, BY GENETIC MUTATIONS, 2018-2030 (USD MILLION)
TABLE 213. AUSTRALIA BREAST CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 214. AUSTRALIA BREAST CANCER SCREENING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 215. AUSTRALIA BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 216. AUSTRALIA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 217. AUSTRALIA BREAST CANCER SCREENING MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 218. AUSTRALIA BREAST CANCER SCREENING MARKET SIZE, BY IMAGING DEVICES, 2018-2030 (USD MILLION)
TABLE 219. AUSTRALIA BREAST CANCER SCREENING MARKET SIZE, BY PAYMENT MODELS, 2018-2030 (USD MILLION)
TABLE 220. AUSTRALIA BREAST CANCER SCREENING MARKET SIZE, BY BREAST DENSITY, 2018-2030 (USD MILLION)
TABLE 221. AUSTRALIA BREAST CANCER SCREENING MARKET SIZE, BY SCREENING INTERVALS, 2018-2030 (USD MILLION)
TABLE 222. CHINA BREAST CANCER SCREENING MARKET SIZE, BY SCREENING METHODS, 2018-2030 (USD MILLION)
TABLE 223. CHINA BREAST CANCER SCREENING MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 224. CHINA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2030 (USD MILLION)
TABLE 225. CHINA BREAST CANCER SCREENING MARKET SIZE, BY MAMMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 226. CHINA BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 227. CHINA BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 228. CHINA BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 229. CHINA BREAST CANCER SCREENING MARKET SIZE, BY RISK FACTORS, 2018-2030 (USD MILLION)
TABLE 230. CHINA BREAST CANCER SCREENING MARKET SIZE, BY GENETIC MUTATIONS, 2018-2030 (USD MILLION)
TABLE 231. CHINA BREAST CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 232. CHINA BREAST CANCER SCREENING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 233. CHINA BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 234. CHINA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 235. CHINA BREAST CANCER SCREENING MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 236. CHINA BREAST CANCER SCREENING MARKET SIZE, BY IMAGING DEVICES, 2018-2030 (USD MILLION)
TABLE 237. CHINA BREAST CANCER SCREENING MARKET SIZE, BY PAYMENT MODELS, 2018-2030 (USD MILLION)
TABLE 238. CHINA BREAST CANCER SCREENING MARKET SIZE, BY BREAST DENSITY, 2018-2030 (USD MILLION)
TABLE 239. CHINA BREAST CANCER SCREENING MARKET SIZE, BY SCREENING INTERVALS, 2018-2030 (USD MILLION)
TABLE 240. INDIA BREAST CANCER SCREENING MARKET SIZE, BY SCREENING METHODS, 2018-2030 (USD MILLION)
TABLE 241. INDIA BREAST CANCER SCREENING MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 242. INDIA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2030 (USD MILLION)
TABLE 243. INDIA BREAST CANCER SCREENING MARKET SIZE, BY MAMMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 244. INDIA BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 245. INDIA BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 246. INDIA BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 247. INDIA BREAST CANCER SCREENING MARKET SIZE, BY RISK FACTORS, 2018-2030 (USD MILLION)
TABLE 248. INDIA BREAST CANCER SCREENING MARKET SIZE, BY GENETIC MUTATIONS, 2018-2030 (USD MILLION)
TABLE 249. INDIA BREAST CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 250. INDIA BREAST CANCER SCREENING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 251. INDIA BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 252. INDIA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 253. INDIA BREAST CANCER SCREENING MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 254. INDIA BREAST CANCER SCREENING MARKET SIZE, BY IMAGING DEVICES, 2018-2030 (USD MILLION)
TABLE 255. INDIA BREAST CANCER SCREENING MARKET SIZE, BY PAYMENT MODELS, 2018-2030 (USD MILLION)
TABLE 256. INDIA BREAST CANCER SCREENING MARKET SIZE, BY BREAST DENSITY, 2018-2030 (USD MILLION)
TABLE 257. INDIA BREAST CANCER SCREENING MARKET SIZE, BY SCREENING INTERVALS, 2018-2030 (USD MILLION)
TABLE 258. INDONESIA BREAST CANCER SCREENING MARKET SIZE, BY SCREENING METHODS, 2018-2030 (USD MILLION)
TABLE 259. INDONESIA BREAST CANCER SCREENING MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 260. INDONESIA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2030 (USD MILLION)
TABLE 261. INDONESIA BREAST CANCER SCREENING MARKET SIZE, BY MAMMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 262. INDONESIA BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 263. INDONESIA BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 264. INDONESIA BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 265. INDONESIA BREAST CANCER SCREENING MARKET SIZE, BY RISK FACTORS, 2018-2030 (USD MILLION)
TABLE 266. INDONESIA BREAST CANCER SCREENING MARKET SIZE, BY GENETIC MUTATIONS, 2018-2030 (USD MILLION)
TABLE 267. INDONESIA BREAST CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 268. INDONESIA BREAST CANCER SCREENING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 269. INDONESIA BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 270. INDONESIA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 271. INDONESIA BREAST CANCER SCREENING MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 272. INDONESIA BREAST CANCER SCREENING MARKET SIZE, BY IMAGING DEVICES, 2018-2030 (USD MILLION)
TABLE 273. INDONESIA BREAST CANCER SCREENING MARKET SIZE, BY PAYMENT MODELS, 2018-2030 (USD MILLION)
TABLE 274. INDONESIA BREAST CANCER SCREENING MARKET SIZE, BY BREAST DENSITY, 2018-2030 (USD MILLION)
TABLE 275. INDONESIA BREAST CANCER SCREENING MARKET SIZE, BY SCREENING INTERVALS, 2018-2030 (USD MILLION)
TABLE 276. JAPAN BREAST CANCER SCREENING MARKET SIZE, BY SCREENING METHODS, 2018-2030 (USD MILLION)
TABLE 277. JAPAN BREAST CANCER SCREENING MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 278. JAPAN BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2030 (USD MILLION)
TABLE 279. JAPAN BREAST CANCER SCREENING MARKET SIZE, BY MAMMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 280. JAPAN BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 281. JAPAN BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 282. JAPAN BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 283. JAPAN BREAST CANCER SCREENING MARKET SIZE, BY RISK FACTORS, 2018-2030 (USD MILLION)
TABLE 284. JAPAN BREAST CANCER SCREENING MARKET SIZE, BY GENETIC MUTATIONS, 2018-2030 (USD MILLION)
TABLE 285. JAPAN BREAST CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 286. JAPAN BREAST CANCER SCREENING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 287. JAPAN BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 288. JAPAN BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 289. JAPAN BREAST CANCER SCREENING MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 290. JAPAN BREAST CANCER SCREENING MARKET SIZE, BY IMAGING DEVICES, 2018-2030 (USD MILLION)
TABLE 291. JAPAN BREAST CANCER SCREENING MARKET SIZE, BY PAYMENT MODELS, 2018-2030 (USD MILLION)
TABLE 292. JAPAN BREAST CANCER SCREENING MARKET SIZE, BY BREAST DENSITY, 2018-2030 (USD MILLION)
TABLE 293. JAPAN BREAST CANCER SCREENING MARKET SIZE, BY SCREENING INTERVALS, 2018-2030 (USD MILLION)
TABLE 294. MALAYSIA BREAST CANCER SCREENING MARKET SIZE, BY SCREENING METHODS, 2018-2030 (USD MILLION)
TABLE 295. MALAYSIA BREAST CANCER SCREENING MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 296. MALAYSIA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2030 (USD MILLION)
TABLE 297. MALAYSIA BREAST CANCER SCREENING MARKET SIZE, BY MAMMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 298. MALAYSIA BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 299. MALAYSIA BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 300. MALAYSIA BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 301. MALAYSIA BREAST CANCER SCREENING MARKET SIZE, BY RISK FACTORS, 2018-2030 (USD MILLION)
TABLE 302. MALAYSIA BREAST CANCER SCREENING MARKET SIZE, BY GENETIC MUTATIONS, 2018-2030 (USD MILLION)
TABLE 303. MALAYSIA BREAST CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 304. MALAYSIA BREAST CANCER SCREENING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 305. MALAYSIA BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 306. MALAYSIA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 307. MALAYSIA BREAST CANCER SCREENING MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 308. MALAYSIA BREAST CANCER SCREENING MARKET SIZE, BY IMAGING DEVICES, 2018-2030 (USD MILLION)
TABLE 309. MALAYSIA BREAST CANCER SCREENING MARKET SIZE, BY PAYMENT MODELS, 2018-2030 (USD MILLION)
TABLE 310. MALAYSIA BREAST CANCER SCREENING MARKET SIZE, BY BREAST DENSITY, 2018-2030 (USD MILLION)
TABLE 311. MALAYSIA BREAST CANCER SCREENING MARKET SIZE, BY SCREENING INTERVALS, 2018-2030 (USD MILLION)
TABLE 312. PHILIPPINES BREAST CANCER SCREENING MARKET SIZE, BY SCREENING METHODS, 2018-2030 (USD MILLION)
TABLE 313. PHILIPPINES BREAST CANCER SCREENING MARKET SIZE, BY BIOPSY, 2018-2030 (USD MILLION)
TABLE 314. PHILIPPINES BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), 2018-2030 (USD MILLION)
TABLE 315. PHILIPPINES BREAST CANCER SCREENING MARKET SIZE, BY MAMMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 316. PHILIPPINES BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, 2018-2030 (USD MILLION)
TABLE 317. PHILIPPINES BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2030 (USD MILLION)
TABLE 318. PHILIPPINES BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 319. PHILIPPINES BREAST CANCER SCREENING MARKET SIZE, BY RISK FACTORS, 2018-2030 (USD MILLION)
TABLE 320. PHILIPPINES BREAST CANCER SCREENING MARKET SIZE, BY GENETIC MUTATIONS, 2018-2030 (USD MILLION)
TABLE 321. PHILIPPINES BREAST CANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 322. PHILIPPINES BREAST CANCER SCREENING MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 323. PHILIPPINES BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 324. PHILIPPINES BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030

Companies Mentioned

  • AstraZeneca plc
  • Bayer AG
  • Becton, Dickinson and Company
  • Carestream Health, Inc.
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Fujifilm Holdings Corporation
  • GE HealthCare Technologies Inc.
  • GlaxoSmithKline plc
  • Hologic, Inc.
  • Koning Health
  • Koninklijke Philips N.V.
  • Myriad Genetics, Inc.
  • NanoString Technologies, Inc.
  • NIRAMAI Health Analytix Private Limited
  • Novartis AG
  • Oncocyte Corporation
  • OncoStem Diagnostics Pvt. Ltd
  • Pfizer Inc.
  • Prelude Corporation
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Syantra Inc.
  • Vayyar Imaging, Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Next-Generation Breast Cancer Diagnostic & Screening Market by Product, Diagnostic Technology, Screening Technology, Application, End User - Global Forecast 2025-2030 - Product Image

Next-Generation Breast Cancer Diagnostic & Screening Market by Product, Diagnostic Technology, Screening Technology, Application, End User - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
Breast Cancer Diagnostics Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Breast Cancer Diagnostics Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 196 Pages
  • Global
From
Breast Cancer Diagnostics Market Report 2025 - Product Image

Breast Cancer Diagnostics Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Global Breast Cancer Screening Test - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Global Breast Cancer Screening Test - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 115 Pages
  • Global
From
Breast Cancer Screening - Global Strategic Business Report - Product Image

Breast Cancer Screening - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From

About the Breast Cancer Screening Market

The Breast Cancer Screening market is a key component of Women's Health. It is a preventative measure that helps to detect breast cancer in its early stages, when it is most treatable. Screening typically involves mammography, which is an X-ray imaging test that can detect changes in the breast tissue. Other screening methods include clinical breast exams, breast ultrasounds, and MRI scans. The Breast Cancer Screening market is a growing industry, with many companies offering services to women. These companies provide a range of services, from mammography to MRI scans, to help women detect breast cancer early. Companies in the Breast Cancer Screening market include Breastlink, Breast Cancer Diagnostics, and Breast Health Solutions. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.